A meta-study of sarcopenia involving 4,904 community-living and institutional older adults (68-87.6 years) from 9 countries and another meta-analysis of 4,071 participants from 5 countries showed that regardless of age and setting, albumin is negatively associated with sarcopenia, which is easier and less costly to implement than other approaches and ensures timely assessment and early intervention in older adults patients with sarcopenia, Therefore, serum albumin decline can be considered as a reference indicator for biomarkers of sarcopenia. This evidence concerns the gene ALB and sarcopenia.